Literature DB >> 22642330

Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma.

Maria Muccioli1, Caitlin Longstaff, Fabian Benencia.   

Abstract

Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. It has been considered that, similar to what has been observed in the context of immunological responses towards microbes, CD4 help is indispensable for the development of a successful and long-lasting (memory) CD8 immune response. In the recent article, Côté et al. reported that, in a mouse model of melanoma, total ablation of CD4 help does not hamper the development of a specific antitumor memory CD8 response. In addition, ablation of CD4 was more successful than strategies to deplete CD25 Tregs in generating memory CD8 T cells. These data opens the door for therapies destined to induce effective antitumor immune responses by ablation of whole CD4 T-cell populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22642330      PMCID: PMC3392304          DOI: 10.2217/imt.12.39

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  38 in total

Review 1.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

2.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in self-tolerance and autoimmune disease.

Authors:  S Sakaguchi; R Setoguchi; H Yagi; T Nomura
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

3.  Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells.

Authors:  Simon J Prasad; Kathryn J Farrand; Stephanie A Matthews; Joe H Chang; Rebecca S McHugh; Franca Ronchese
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

Review 4.  Helicobacter infection and gastric neoplasia.

Authors:  Richard M Peek; Jean E Crabtree
Journal:  J Pathol       Date:  2006-01       Impact factor: 7.996

Review 5.  Colon cancer and the immune system: the role of tumor invading T cells.

Authors:  Maximilian Waldner; Carl-C Schimanski; Markus-F Neurath
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

Review 6.  Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.

Authors:  Claudia Wrzesinski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2005-04       Impact factor: 7.486

Review 7.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

Review 8.  Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Authors:  Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo
Journal:  Nat Clin Pract Oncol       Date:  2006-12

Review 9.  Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions.

Authors:  Curzio Rüegg
Journal:  J Leukoc Biol       Date:  2006-07-18       Impact factor: 4.962

10.  Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.

Authors:  S S Legha; M A Gianan; C Plager; O E Eton; N E Papadopoulous
Journal:  Cancer       Date:  1996-01-01       Impact factor: 6.860

View more
  1 in total

1.  Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring.

Authors:  Amanda Bulman; Monica Neagu; Carolina Constantin
Journal:  Curr Proteomics       Date:  2013-09       Impact factor: 0.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.